18 October 2024
18 October 2024
With less than three weeks until Americans cast their vote, what would healthcare look under a Harris or Trump administration?
Strategic restructuring will support the ongoing launch of the oral postpartum depression drug, Zurzuvae, and extend Sage’s cash runway.
The company’s keratoconus medication, Epioxa, was effective in a Phase III trial, with plans to file for submission with the US Food and Drug Administration (FDA).
Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.
The US represents the largest market for opioid addiction with 74.1% of 8MM sales, due to its larger addict population and the high price of medication.
The FDA's approval is based on results from the pivotal Phase III M15-736 study.
Sanofi’s equity investment will give it a 16% stake in the new entity valued at €1.9bn.
News of this potential agreement comes before a milestone year in 2025, when the country's clawback mechanism is due to expire.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
